$24,750.00 | '
Delayed Sleep-Wake Phase Disorder | Executive Insights | US/EU5 | 2021
- DSWPD is a type of circadian rhythm sleep-wake disorder in which the sleep-wake cycle is delayed. DSWPD occurs more commonly in adolescents than in adults. In addition, the condition is highly comorbid with some psychiatric conditions, such as MDD and ASD.
- Although interviewed sleep specialists commonly diagnose DSWPD, they cite challenges in differentiating circadian DSWPD from noncircadian (i.e., behavioral) DSWPD. Interviewed psychiatrists usually consider DSWPD as secondary to a psychiatric disorder.
- No drug is currently approved for the management of DSWPD in the United States and EU5. Melatonin and some nonpharmacological approaches (e.g., light therapy) are commonly utilized in the treatment of DSWPD. However, the patient journey may differ depending on the presence or absence of a comorbid psychiatric disorder.
- Interviewed physicians cite multiple areas of unmet need in DSWPD, so opportunities exist for drug development in DSWPD. Of note, interviewed physicians have high expectations for an emerging drug in DSWPD.
Related Market Assessment Reports
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
